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The definition of hypopnoea varies widely between sleep laboratories. This study sought to evaluate the impact upon 
therapeutic decision of the most commonly used one, which defines hypopnoea as a reduction in airflow of 50% (or 
more) accompanied by a decreased blood oxygen saturation of 4% (or more) (Agency for Health Care Policy and 
Research). We studied 109 consecutive patients (99 male) with an apnoea-hypopnoea index (AHI) greater than 5. 
The same investigator evaluated each patient twice. First, the hypopnoea index (HI) was unavailable to him by study 
design, and judgment was based upon the number of apnoeas and the clinical situation of the patient. Thereafter, 
he evaluated all patients again, in random order, this time taking into account the AH1 and the clinical condition of 
the patient. Therapeutic decision was compared at the end of the study. 
Mean age was 54 f 11 years ( f SD) and body mass index 33 f 6 kg m ~ 2. Most patients had normal spirometry 
and day-time arterial blood gases. Mean apnoea index (Al) was 35 & 24 h ~ ‘. Therapeutic decision based on the AI 
lead to conservative treatment (diet and sleep hygiene) in 32 cases and to active treatment in 77 patients [76 
continuous positive airway pressure (CPAP) and one surgery]. The AH1 was 40 f 24 h - ‘. The consideration of the 
number of hypopnoeas lead to a therapeutic change only in four patients (3.7%) k2=0.36, P>O.3). These four 
patients had an AI of 15, 7, 3, and 9 h ’ and an AH1 of 22, 10, 46, and 17 h- ‘, respectively. Combined with their 
clinical data, this increase was considered a requirement for active treatment (CPAP). The most commonly used 
definition of hypopnoea has a small impact upon therapeutic decision in patients with obstructive sleep apnoea 
syndrome (OSAS). We suggest the need to develop new definitions of hypopnoea that incorporate other variables 
(neurophysiological, cardiovascular) of potential clinical relevance. Our results also show that the outcome of any 
new definition has to be assessed rigorously in terms of its clinical impact. 
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Introduction 
The diagnosis of obstructive sleep apnoea syndrome 
(OSAS) requires overnight monitoring of neurophysiologi- 
cal and cardiopulmonary variables (polysomnography) to 
quantify, among other things, the number of apnoeas and 
hypopnoeas during sleep (1,2). Apnoea is unanimously 
defined as cessation in airflow of 10 s duration or longer 
(3,4). By contrast, there is no consensus on the definition of 
hypopnoea. A recent study (5) showed that, among 45 sleep 
laboratories in U.S.A. the reduction in airflow required to 
meet criteria for hypopnoea oscillates between any and 
500/o, and the degree of arterial oxygen desaturation 
between any and 4%. This heterogeneity of definitions 
renders the comparison of results among different labora- 
tories difficult. However, to arrive at an unanimously 
agreed definition of hypopnoea would be important only if 
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it has a clear impact on clinical practice. We undertook the 
current study to evaluate the impact upon the therapeutic 
decision of the definition of hypopnoea most commonly 
used in different laboratories (5), which is a reduction in 
airflow of 50% (or more), accompanied by decrease of 
blood oxygen saturation of 4% (or more) (Agency for 
Health Care Policy and Research) (3). 
Methods 
We included in the study all the patients with an apnoea- 
hypopnoea index (AHI) greater than 5 h - ’ attending by 
the Sleep Unit of our institution from July 1993 until 
December 1994. As part of their routine clinical evaluation 
all of them completed a questionnaire focused on sleep- 
related symptoms. Also, we measured day-time arterial 
blood gases (IL BG3, Izasa, Spain) and forced spirometry 
(Warren E. Collins, MA, U.S.A.), and we obtained an 
EKG and a chest X-ray. An ENT evaluation was carried 
out only when clinically indicated. Occupational history 
was recorded. Nocturnal polysomnography (Ultrasom 
Nicolett, WI, U.S.A.) was obtained in all subjects during 
the first night in the sleep laboratory. It included recording 
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of oro-nasal flow by thermocouples (Pro-Tech Services, Inc. 
Woodinville, WA, U.S.A.) mounted on nasal prongs, 
thoraco-abdominal movements by stripes of stretching, sub- 
mental electromyogram, electroculogram, electroencepha- 
logram (C,A,, C,A,), electrocardiogram (DII derivation 
modified) and oxygen saturation (Criticare Systems Inc, 
WI, U.S.A.). Sleep stages scoring was done according to 
Rechtschaffen and Kales (6). 
Apnoea was defined as a cessation in airflow of 10 s or 
longer (3,4). Hypopnoea was defined as a reduction in 
airflow of 50% or more, accompanied by a decreased blood 
oxygen saturation of 4% or more with respect to baseline 
(3). Following the recommendations of the Spanish Society 
of Pulmonology and Thoracic Surgery (SEPAR) (4): (1) 
conservative treatment (diet and sleep hygiene) was advised 
whenever the AH1 was lower than 10; (2) an AH1 greater 
than 20 h ’ was considered as a criterion for active treat- 
ment. usually with continuous positive airway pressure 
(CPAP); and (3) when the AH1 was between 10 and 20 h ‘, 
therapeutic decision was individualized and based upon 
clinical data (mainly day-time symptoms, cardiovascular 
risk factors and occupation) and arterial blood gas data. 
The same investigator (F.B.) evaluated each chart (includ- 
ing clinical, functional and polygraphic data) on two sep- 
arate occasions. First, with the hypopnoea index (HI) 
unavailable to him by study design; judgement was based 
upon the number of apnoeas and the clinical situation of 
the patients. Thereafter he evaluated all charts again, in 
random order (without knowing the previous decision), this 
time taking into account the AH1 and the clinical condition 
of the patient. At the end of the study, therapeutic decision 
was compared. This type of design is similar to that 
used by Douglas et u/. (7) to assess the clinical value of 
polysomnography in patients referred to a sleep unit. 
Results are shown as mean f standard deviation (SD) and 
range. The normal distribution of the data was confirmed 
using the Kolmogorov-Smirnov test. Differences between 
sample proportions were analysed by the Xl-test. The 
relationship between the apnoea index (AI) and the AH1 
was assessed using the Spearman correlation test. A P value 
lower than 0.05 was considered significant. 
Results 
We studied 109 consecutive patients (99 male) with a mean 
age of 54 f 11 years. Each patient had at least one (mean 3; 
range l-7) of the following clinical features: a history of 
loud snoring, unsatisfying nocturnal sleep, disturbed sleep, 
changes of mood in the last months, morning headache, 
excessive day-time somnolence, cardiovascular disease and/ 
or polycythaemia. Table 1 presents their anthropometric. 
blood gas and spirometric data. Overall, patients were 
mildly obese and showed normal spirometry and day-time 
arterial blood gases, although wide inter-individual vari- 
ation existed (Table 1). Table 2 shows the polysomno- 
graphic data. By definition, all patients had an AH1 greater 
than 5 h ~ ‘_ Mean AI was 35 h ~ ’ ( & 24) and mean AH1 
was 40 h - ’ ( f 24) (Table 2). There was no significant 
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TABLE 1. Anthropometric, gasometric and spirometric data 
Mean f SD Range 
Age (years) 54* 11 2482 
Body mass index (kg ~ m ‘) 33 f 6 21-53 
PaO, (mmHg) 77% 13 39-100 
PaCO, (mmHg) 41 f 16 3ll80 
FEV, (% ref) 85 f 21 299136 
FEVJFVC (X,) 94& 16 40-122 
FEV,, Forced expiratory volume in I s. FVC, Forced vital 
capacity. Reference values were those of Rota et al. (8). 
TABLE 2. Polysomnographic data 
Mean f SD Range 
Apnoea index (h - ‘) 
Apnoea-hypopnoea index (h ~ ‘) 
Total sleep time (min) 
Sleep efficiency (0%) 
REM stage (%I) 
1 +2 stage (‘l/u) 
3+4 stage (‘%) 
Minimum arterial 0, saturation 
at night (%) 
Mean arterial 0, saturation 
at night (‘Z,) 
Time under 90% 0, saturation 
at night (min) 
35&24 
40 f 24 
404 f I 
89 f 12 
16+ 12 
693 18 
16114 
7oi 13 
9oi 8 
123 f 130 
O-98 
5-98 
203-509 
499100 
O-72 
13-100 
O-84 
41-99 
57-99 
o-497 
50, 
I p : -0.1 . P= 0.3 ^ 40 
. 
. 
Number of apnoeas (h-l) 
FIG. 1. Lack of relationship between the number of 
apnoeas h ’ and the number of hypopnoeas h - ’ in all 
the patients studied. 
relationship between the AI and the AH1 @: - 0.1; P=O.3) 
(Fig. 1). 
Therapeutic decision based upon the AI alone led to 
conservative treatment (diet and sleep hygiene) in 32 cases 
and to active treatment in 77 patients (76 CPAP and one 
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surgery). When the same patients were evaluated using the 
AHI, conservative treatment was indicated in 28 cases and 
active treatment in 81 individuals @=0.36, P>O.3). Only in 
four out of the 109 patients studied (3.7%) therapeutic 
decision changed by considering the AHI. All four patients 
had an AI lower than 20 h - ’ (15, 7, 3 and 9 h - ’ . Their 
AH1 was 22, 10, 46 and 17 h-i, respectively. Combined 
with their clinical data, this change was considered a 
requirement for active treatment (CPAP). These four 
patients represent 11% of patients with an AI<20 h- ‘. 
Discussion 
This investigation sought to assess the impact upon thera- 
peutic decision of the most commonly used definition 
of hypopnoea (reduction of airflow of 50% or more 
accompanied by decreased blood oxygen saturation of 4% 
or more) (5). This is the definition recommended by the 
Agency for Health Care Policy and Research (3). Our 
results show that it has a minor clinical impact because, by 
considering the presence of hypopnoeas, a change in 
therapeutic decision occurred only in 3.7% of the patients. 
A recent study, has shown that there is enormous vari- 
ability of the definition of hypopnoea among different labo- 
ratories (5). There is no consensus on the degree of airflow 
reduction required to categorize an event as hypopnoea, or 
on how to measure it, or if hypopnoea has to be defined as 
a function of the reduction in airflow or thoracoabdominal 
movements, or even on what neurological events (sleep 
fragmentation, change of frequency in electroencephalo- 
graph) (9) should be associated with airflow reduction in 
order to consider it as clinically significant. Consequently, 
many laboratories use their own definition of hypopnoea, 
making comparison of the results difficult and, more impor- 
tantly, without having a clear knowledge of the real out- 
come of each definition. Our results apply to a particular 
definition of hypopnoea. Although this is the definition 
most commonly used in different laboratories (5), our 
results can not be extrapolated directly to all definitions 
currently in use. Within this conceptual frame though, our 
study underscores the small clinical impact of this definition 
and suggests that, if hypopnoeas really have to be incorpor- 
ated into clinical judgement, other definitions should be 
evaluated. Our current records do not allow us to explore 
other alternatives in the population investigated herein. 
Previous studies (10) have shown that hypopnoeas can: 
(1) induce transitory awakenings (arousals) that fragment 
sleep and causes day-time sleepiness (10,ll); (2) associate 
intrathoracic pressure changes due to partial occlusion of 
the upper airway that lead to cardiocirculatory and haemo- 
dynamics disturbances (12); and (3) stimulate the sympa- 
thetic nervous system (13,14). The definition of hypopnoea 
evaluated in the present study does not include any of these 
potential consequences of hypopnoea. Given its small 
impact on clinical practice, we suggest that any future 
definition would probably need to include some of these 
neurological and/or cardiovascular parameters (9). 
Several methodological limitations should be considered. 
On the one hand, the possibility that we had mistaken 
hypopnoeas for apnoeas. We believe that this is unlikely 
because, we used standard methodology (see Methods), and 
the number of hypopnoeas we observed was similar to that 
reported previously (1.516). On the other, we can not 
completely exclude some intra-observer variability in the 
therapeutic decision chosen. However, we think that this is 
probably minor because the short duration of the study (18 
months) allowed us not to change the therapeutic protocol 
used. Further, this was easy to follow but rigid enough as to 
minimize this potential effect. 
In summary, our study shows that the most commonly 
used definition of hypopnoea (Agency for Health Care and 
Research) (3) has a small impact on therapeutic decision in 
patients with an AH1 greater than 5 h - ‘. We suggest the 
need to develop new definitions of hypopnoea that incor- 
porate other variables (neurophysiological, cardiovascular) 
of potential relevance (9). From our results, it is also clear 
that the impact of any new definition has to be assessed 
rigorously in terms of its clinical outcome. 
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